HIV/AIDS News and Research RSS Feed - HIV/AIDS News and Research Twitter

Acquired immune deficiency syndrome or acquired immunodeficiency syndrome (AIDS) is a disease of the human immune system caused by the human immunodeficiency virus (HIV).

This condition progressively reduces the effectiveness of the immune system and leaves individuals susceptible to opportunistic infections and tumors. HIV is transmitted through direct contact of a mucous membrane or the bloodstream with a bodily fluid containing HIV, such as blood, semen, vaginal fluid, preseminal fluid, and breast milk.
Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Northwestern Medicine scientists have received a five-year, $17.5 million grant from the National Institutes of Health for an interdisciplinary project that aims to invent, develop and test an implantable drug delivery system to protect high-risk individuals from HIV infection for up to a year at a time. [More]

Pitt investigators to lead $5 million initiative to monitor resistance to HIV prevention drugs in sub-Saharan Africa

Infectious diseases researchers from the University of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to monitor drug resistance during the rollout of HIV prevention drugs in sub-Saharan Africa. [More]
amfAR releases recommendations to help U.S. states to achieve goals of National HIV/AIDS Strategy

amfAR releases recommendations to help U.S. states to achieve goals of National HIV/AIDS Strategy

Major achievements have been made in the domestic HIV/AIDS response as a result of increased realignment and coordination of efforts at the federal level. However, that level of consistent coordination and alignment has yet to take place in most states. In an effort to identify what needs to be done, amfAR, The Foundation for AIDS Research, in collaboration with the National HIV/AIDS Initiative at the O'Neill Institute for National and Global Health Law at Georgetown Law, has released a set of recommendations for how states across the U.S. can improve HIV prevention and care outcomes in an effort to achieve the goals identified within the National HIV/AIDS Strategy. [More]

Mylan receives regulatory clearance from European Commission for proposed acquisition of Perrigo

Mylan N.V. today announced that it received regulatory clearance from the European Commission under the European Union Merger Regulation (EUMR) for its proposed acquisition of Perrigo Company plc. [More]
New WFSJ initiative to help journalists report on staggering toll of HCV

New WFSJ initiative to help journalists report on staggering toll of HCV

The World Federation of Science Journalists is launching a new initiative to help journalists report on the staggering toll of Hepatitis C (HCV) as well as the scientific and political barriers to treating the disease. [More]

World Hepatitis Alliance partners with WHO to raise awareness on viral hepatitis

The World Hepatitis Alliance, and its supporters today asks the public, the hepatitis community and governments to raise awareness of the 4000 people who die from viral hepatitis every day. [More]
Cepheid, FIND unveil new portable molecular diagnostics system for patients suspected of TB, HIV and Ebola

Cepheid, FIND unveil new portable molecular diagnostics system for patients suspected of TB, HIV and Ebola

Cepheid and FIND today unveiled the GeneXpert Omni, the world's most portable molecular diagnostics system enabling unprecedented access to accurate, fast and potentially life-saving diagnosis for patients suspected of TB, HIV and Ebola in even the most remote areas of the world. [More]
TSRI awarded two grants to support development of effective vaccine against HIV/AIDS

TSRI awarded two grants to support development of effective vaccine against HIV/AIDS

The Scripps Research Institute has been awarded two grants from the Bill & Melinda Gates Foundation totaling more than $4.5 million to fund efforts to develop a vaccine against HIV/AIDS. [More]
Screening for HIV in pregnancy eliminates vertical transmission

Screening for HIV in pregnancy eliminates vertical transmission

Canada has almost eliminated mother-to-child HIV transmission, known as vertical transmission, in recent years by ensuring that all women have the opportunity to be screened for HIV in pregnancy and that women with the disease receive treatment before giving birth. [More]
EGPAF calls for prioritizing HIV treatment among children

EGPAF calls for prioritizing HIV treatment among children

As the HIV/AIDS community gathers for the International AIDS Society Conference in Vancouver, Canada, the Elizabeth Glaser Pediatric AIDS Foundation joins the Vancouver Consensus in calling for universal treatment for all people living with HIV, regardless of CD4 count. Providing treatment for everyone living with HIV will be a paradigm shift in HIV treatment and prevention efforts, particularly for children living with HIV, and will save millions of lives. [More]
Early antiretroviral treatment prevents AIDS- and non-AIDS-related diseases in HIV-infected people

Early antiretroviral treatment prevents AIDS- and non-AIDS-related diseases in HIV-infected people

Starting antiretroviral therapy early not only prevents serious AIDS-related diseases, but also prevents the onset of cancer, cardiovascular disease, and other non-AIDS-related diseases in HIV-infected people, according to a new analysis of data from the Strategic Timing of AntiRetroviral Treatment (START) study, the first large-scale randomized clinical trial to establish that earlier antiretroviral treatment benefits all HIV-infected individuals. [More]
Young, single South African women adhere well to daily PrEP regimen to prevent HIV infection

Young, single South African women adhere well to daily PrEP regimen to prevent HIV infection

A clinical study funded by the National Institutes of Health has found that young, single black women in South Africa adhered to a daily pill regimen to prevent HIV infection--an HIV prevention strategy known as pre-exposure prophylaxis, or PrEP. This finding is the first strong indication that this population at substantial HIV risk could accept and reliably adhere to daily PrEP dosing. [More]
Study findings provide basis for potential development of new methods to control HIV infection

Study findings provide basis for potential development of new methods to control HIV infection

Lower levels of cholesterol in certain immune cells--a result of enhanced cholesterol metabolism within those cells--may help explain why some HIV-infected people are able to naturally control disease progression, according to research that will be presented in a poster at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) in Vancouver, Canada, and the pre-conference 2015 Towards an HIV Cure Symposium. [More]
Canadian researchers discover how HIV evades the body's antiviral responses

Canadian researchers discover how HIV evades the body's antiviral responses

A Canadian research team at the IRCM in Montreal, led by molecular virologist Eric A. Cohen, PhD, made a significant discovery on how HIV escapes the body's antiviral responses. The team uncovered how an HIV viral protein known as Vpu tricks the immune system by using its own regulatory process to evade the host's first line of defence. [More]
Ebola vaccine study begins in Dakar, Senegal

Ebola vaccine study begins in Dakar, Senegal

A trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial immunisations started at the Jenner Institute, Oxford University. The announcement comes as a conference in Oxford discusses the global response to Ebola and the implications for future drug and vaccine development. [More]
Mylan announces launch of generic Namenda Tablets in U.S.

Mylan announces launch of generic Namenda Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, which is the generic version of Forest's Namenda Tablets. [More]

New report highlights key success in global response to preventing AIDS in women, children

The Elizabeth Glaser Pediatric AIDS Foundation applauds today's announcement from the Joint United Nations Programme on HIV/AIDS that the goal of providing 15 million people with lifesaving antiretroviral therapy (ART) by 2015 has been met nine months ahead of schedule. [More]
Starting anti-HIV treatment early improves survival among patients with newly diagnosed TB

Starting anti-HIV treatment early improves survival among patients with newly diagnosed TB

Starting anti-HIV treatment within two weeks of the diagnosis of tuberculosis, or TB, improved survival among patients with both infections who had very low immune-cell counts, according to an analysis by researchers at the University of Pittsburgh Graduate School of Health. [More]
Mylan announces launch of Bexarotene 75mg Capsules in U.S.

Mylan announces launch of Bexarotene 75mg Capsules in U.S.

Mylan N.V. today announced the U.S. launch of Bexarotene 75mg Capsules, which is the generic version of Valeant's Targretin Capsules. This product is indicated for the treatment of cutaneous manifestations of cutaneous t-cell lymphoma in patients who are refractory to at least one prior systemic therapy. [More]
Three South Florida research centers receive Campbell Foundation grants for HIV/AIDS studies

Three South Florida research centers receive Campbell Foundation grants for HIV/AIDS studies

New research is taking place all around the world in the fight to find a cure for AIDS. But did you know that some critical research is taking place in our own backyard? That’s why The Campbell Foundation recently provided three South Florida research centers each with $30,000 fast-track grants to assist them with their ground-breaking investigations. [More]
Advertisement